Variation of rs3754689 at lactase gene and inhibitors in admixed Brazilian patients with hemophilia A

Hemophilia A is an X-linked bleeding disorder due to mutations in the factor VIII gene (F8). The most clinically relevant complication of hemophilia A is the development of neutralizing alloantibodies (inhibitors) against factor VIII1 , occurring in up to 30% of severe patients. Inhibitors impair hemostasis during FVIII replacement, leading to hemorrhages difficult to control, disability and decreased quality of life. The use of bypassing agents is required in most cases to treat or prevent bleeding, representing a more expensive and less effective alternative hemostatic therapy than exogenous FVIII.